Quick Answer
HALOZYME THERAPEUTICS, INC. reported Research And Development Expense of $79.05 million for the year ending 2024.
- HALOZYME THERAPEUTICS, INC. showed an increase of +3.5% in Research And Development Expense from 2023 to 2024.
- This data is from HALOZYME THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 18, 2025.
- XBRL data for this metric is available from 2009 to 2024 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2009 to 2024), HALOZYME THERAPEUTICS, INC.'s Research And Development Expense has grown by 39.6%.
- Historical annual values: Fiscal year 2024: $79.05 million | Fiscal year 2023: $76.36 million | Fiscal year 2022: $66.61 million | Fiscal year 2021: $35.67 million | Fiscal year 2020: $34.24 million | Fiscal year 2019: $140.80 million | Fiscal year 2018: $150.25 million | Fiscal year 2017: $150.64 million | Fiscal year 2016: $150.84 million | Fiscal year 2015: $93.24 million | Fiscal year 2014: $79.70 million | Fiscal year 2013: $96.64 million | Fiscal year 2012: $70.04 million | Fiscal year 2011: $57.56 million | Fiscal year 2010: $51.77 million | Fiscal year 2009: $56.61 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: